New Data for Precision Biologics, Inc. PB-223 ADC against novel tumor-specific target on human cancers revealed at SITC 2026
· prnewswire.com · popularity 16/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at prnewswire.com →
Summary
BETHESDA, Md., Nov. 6, 2026 /PRNewswire/ -- Precision Biologics, Inc. CEO Philip M. Arlen, MD announces presentation of new data describing in-vivo efficacy of its novel tumor-specific antibody-drug-conjugate PB-223 ADC. Recent tumor killing data showing specific non-toxic anti-tumor...
Found in: PR Newswire. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 18.